drugset / Trial / NCT04503980
αPD1-MSLN-CAR T Cells for the Treatment of MSLN-positive Advanced Solid Tumors
Phase 0
Unknown
10 enrolled
Shanghai Cell Therapy Group Co.,Ltd
Shanghai 10th People's Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a single arm, open-label, dose escalation clinical study to evaluate the safety and tolerability of autologous mesothelin (MSLN)-targeted chimeric antigen receptor (MSLN-CAR) T cells secreting PD-1 nanobodies (αPD1-MSLN-CAR T cells) in patients with solid tumors.
Timeline
- Start
- 2020-03-26
- Primary completion
- 2021-03
- Completion
- 2022-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | αPD1-MSLN-CAR T cells | Cell therapy | 100000 cells/kg | Intravenous |
| Subject | αPD1-MSLN-CAR T cells | Cell therapy | 300000 cells/kg | Intravenous |
| Subject | αPD1-MSLN-CAR T cells | Cell therapy | 1e+06 cells/kg | Intravenous |
| Subject | αPD1-MSLN-CAR T cells | Cell therapy | 3e+06 cells/kg | Intravenous |